The US FDA has approved GSK’s Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.
Hepatitis B Breakthrough: GSK's New Drug Hibsago Helped 19% Stay Off Treatment
The US FDA has approved GSK’s Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.